Please enable JavaScript.  This webapp requires JavaScript to work at its best.

Dosing & administration guide

The guide supports healthcare professionals with the dosing and administration of LENVIMA® in their differentiated thyroid cancer (DTC) patients.

It provides guidance on how and when to take LENVIMA®, dose adjustments, and special warnings and precautions for its use. All of the information included is based on the Summary of Product Characteristics.


Supporting documentation:
LENVIMA® 4 mg hard capsules  Summary of Product Characteristics
LENVIMA® 10 mg hard capsules Summary of Product Characteristics


UK-LENA-23-00017  Date of preparation January 2023